Laura Joiner, PharmD, BCOP
Articles by Laura Joiner, PharmD, BCOP
Closing Perspectives and Future Directions in Multiple Myeloma Care
ByZahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Brooke Adams, PharmD, BCOP,Thomas Martin, MD,Raymond Thertulien, MD, PhD,Laura Joiner, PharmD, BCOP Experts discuss the importance of transitioning cancer care from academic centers to community settings, ensuring effective patient management and support.
Transitioning Multiple Myeloma Care from Academic to Community Settings
ByZahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Brooke Adams, PharmD, BCOP,Thomas Martin, MD,Raymond Thertulien, MD, PhD,Laura Joiner, PharmD, BCOP Experts discuss the importance of transitioning cancer care from academic centers to community practices, ensuring patient support and effective communication.
Safety Considerations and Practical Strategies for Using Bispecific Antibodies in Multiple Myeloma
ByZahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Brooke Adams, PharmD, BCOP,Thomas Martin, MD,Raymond Thertulien, MD, PhD,Laura Joiner, PharmD, BCOP Explore the safety considerations and unique toxicities of bispecific antibodies, including cytokine release syndrome and neurotoxicity management.
Role of Antibody-Drug Conjugates in Multiple Myeloma
ByZahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Brooke Adams, PharmD, BCOP,Thomas Martin, MD,Raymond Thertulien, MD, PhD,Laura Joiner, PharmD, BCOP Explore the latest advancements in bispecific antibodies for multiple myeloma, focusing on early treatment opportunities and innovative trial designs.
Opportunities for Earlier Initiation of Bispecific Therapies in Multiple Myeloma
ByZahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Brooke Adams, PharmD, BCOP,Thomas Martin, MD,Raymond Thertulien, MD, PhD,Laura Joiner, PharmD, BCOP Explore the promising results of the REDIRECT trial, combining bispecific therapies for treating relapsed/refractory myeloma with high response rates.
Exploring Combination Bispecific Strategies in Multiple Myeloma with Talquetamab and Teclistamab from RedirecTT-1 Trial
ByZahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Brooke Adams, PharmD, BCOP,Thomas Martin, MD,Raymond Thertulien, MD, PhD,Laura Joiner, PharmD, BCOP Explore the promising results of the REDIRECT trial, combining bispecific therapies for treating relapsed/refractory myeloma with high response rates.
Clinical Insights on the Efficacy and Safety of Bispecific Antibodies in Multiple Myeloma
ByZahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Brooke Adams, PharmD, BCOP,Thomas Martin, MD,Raymond Thertulien, MD, PhD,Laura Joiner, PharmD, BCOP Real-world evidence highlights the effectiveness of teclistamab and elranatamab in treating frail multiple myeloma patients, paving the way for future therapies.
Bispecific Antibody Efficacy and Safety in Multiple Myeloma: Updates from ASH 2025
ByZahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Brooke Adams, PharmD, BCOP,Thomas Martin, MD,Raymond Thertulien, MD, PhD,Laura Joiner, PharmD, BCOP Explore the latest insights on clinical trial data and real-world evidence for innovative cancer therapies, highlighting efficacy and safety.
Evaluating Clinical Trial Data and Real-World Evidence of Bispecific Antibodies in Multiple Myeloma
ByZahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Brooke Adams, PharmD, BCOP,Thomas Martin, MD,Raymond Thertulien, MD, PhD,Laura Joiner, PharmD, BCOP Explore the unique mechanisms of bispecific antibodies and their rapid availability compared to CAR T-cell therapies in cancer treatment.
Mechanisms of Action of Bispecific Antibodies in Multiple Myeloma
ByZahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Brooke Adams, PharmD, BCOP,Thomas Martin, MD,Raymond Thertulien, MD, PhD,Laura Joiner, PharmD, BCOP Explore the unique mechanisms of bispecific antibodies versus CAR T-cell therapies in treating multiple myeloma and their clinical implications.
Bispecific Antibodies in Multiple Myeloma and Practical Definitions of Lines of Therapy
ByZahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Brooke Adams, PharmD, BCOP,Thomas Martin, MD,Raymond Thertulien, MD, PhD,Laura Joiner, PharmD, BCOP Explore the transformative potential of bispecific antibodies in multiple myeloma, offering hope for improved patient outcomes and possible cures.
Addressing Therapeutic Gaps in Multiple Myeloma with Bispecific Antibody Therapies
ByZahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Brooke Adams, PharmD, BCOP,Thomas Martin, MD,Raymond Thertulien, MD, PhD,Laura Joiner, PharmD, BCOP Experts discuss the critical challenges in accessing innovative treatments for relapsed refractory multiple myeloma, emphasizing equity and education.
Challenges in the Management of Relapsed/Refractory Multiple Myeloma
ByZahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Brooke Adams, PharmD, BCOP,Thomas Martin, MD,Raymond Thertulien, MD, PhD,Laura Joiner, PharmD, BCOP Experts discuss the critical challenges in accessing innovative treatments for relapsed refractory multiple myeloma, emphasizing equity and education.
Unmet Needs and Emerging Therapeutic Advances in Multiple Myeloma
ByZahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Brooke Adams, PharmD, BCOP,Thomas Martin, MD,Raymond Thertulien, MD, PhD,Laura Joiner, PharmD, BCOP Experts discuss the evolving role of bispecific antibodies in multiple myeloma, highlighting treatment advancements and strategies for optimal patient care.
